Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Novartis divulges NLRP3 inhibitors

May 18, 2020

FronThera US Pharmaceuticals synthesizes new TYK2 inhibitors

May 18, 2020

Medshine Discovery discloses Wee1 inhibitors

May 18, 2020

TNFAIP2 identified as potential therapeutic target in platinum-resistant urothelial carcinoma

May 18, 2020

Interim phase II data for apalutamide plus abiraterone acetate/prednisone in prostate cancer

May 18, 2020

First-in-human data for novel proliposomal paclitaxel, TSD-001, in NMIBC

May 18, 2020

Genenta presents phase I/II data for Temferon cell-based therapy in patients with GBM

May 18, 2020

FDA approves Pomalyst for AIDS-related and HIV-negative Kaposi sarcoma

May 18, 2020

Identification of a novel series of 1,6-naphthyridinone-based class II MET kinase inhibitors

May 18, 2020

EGFR identified as a target in some retinoblastoma tumors

May 15, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...